This invention relates to an immunoresponsive cell comprising a chimeric NKG2D protein. The immunoresponsive cell is a T-cell, natural killer (NK) cell, macrophage or neutrophil and the chimeric NKG2D protein comprises a human NKG2D extracellular domain or a variant thereof, and a murine NKG2D transmembrane domain or a variant thereof. The disclosure also relates to isolated polynucleotide(s) encoding the chimeric NKG2D protein and the use of the immunoresponsive cells or isolated polynucleotides in therapy or the treatment of cancer.

Described herein are embodiments of chemically modified neutrophils and pharmaceutical formulations thereof. Also described herein are 4-phenylbutyrate pharmaceutical formulations. Also described herein are methods of chemically modifying neutrophils. Also described herein are treatments for non-resolving inflammation and/or related diseases or conditions, including but not limited to atherosclerosis, cardiovascular disease, stroke, myocardial infarction, neurological disease, and/or a symptom thereof in a subject in need thereof.

Provided are an exosome preparation formed by secretion by a mast cell cultured in vitro, a preparation method of an exosome therein, an exosome containing FcεRI protein on an outer surface thereof and in a substantially unbound state, and uses of the exosome preparation or exosome in a method for inhibiting mast cell activation in vitro and in preparing a drug for treating an IgE-mediated disease.

Provided herein are reagents and methods for targeting the ELANE gene for inhibition. Further provided herein is a method for producing a progenitor cell or a population of progenitor cells having decreased ELANE mRNA or protein expression.

The present invention relates to isolated mammalian CD11b+/PIEZO-1+ macrophage cells, neutrophil cells, and/or an isolated exosome as secreted by said cells, pharmaceutical compositions comprising said cells and/or exosomes, as well as uses thereof.

A method of identifying a population of PMN-MDSC-Like Cells (PM-LCs) distinguishable from myeloid derived suppressor cells (PMN-MDSCs). A method for treating a cancer comprising identifying PM-LCs and/or administering an agent that alters neutrophil migration to reduce or inhibit tumor cell seeding, tumor metastasis, or metastatic niche formation in a subject. Compositions for use in diagnosing and treating cancer that comprise antagonists and/or inhibitors of genes and cellular process to alter PM-LC activity.

This disclosure provides methods for producing neutrophils under serum-free and feeder-free conditions from protein tyrosine phosphatase 1B (PTP1b)-inhibited pluripotent stem cells. The disclosure further provides PTP1b inhibited neutrophils and uses thereof. Also disclosed are methods for producing human neutrophil-DC hybrid cells and human neutrophil-DC hybrid cells produced thereby.

The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

The disclosure generally relates to methods for producing macrophages and neutrophils serum-free and feeder-free conditions from SIRPα inhibited pluripotent stem cells. The disclosure further relates to SIRPα inhibited macrophages and neutrophils and uses thereof.

The present invention relates to an isolated cellular targeted delivery system comprising a CD45.sup.+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and an active ingredient as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy, in particular for therapy of cancer.